News - Cardio-vascular, Takeda Pharmaceuticals

Filter

Popular Filters

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Actavis challenges Multaq and Colcrys patents

02-03-2014

Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Takeda out-licenses Edarbi and Edarbyclor

13-09-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a license, development and…

Arbor PharmaceuticalsCardio-vascularEdarbiEdarbyclorLicensingNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Japan briefs: Takeda files for Azilva comb; Sandoz seeks filgrastim biosimilar approval

29-04-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that it submitted a New Drug Application…

Amlodipine BesylateAsia-PacificAzilvaBiotechnologyCardio-vascularEP2006FilgrastimGenericsImmunologicalsNovartisPharmaceuticalRegulationSandozTakeda PharmaceuticalsZarzio

Japan launches for Lotriga and Argamate

11-01-2013

Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

EU Ombudsman wants more transparency concerning medicines for children

04-06-2012

European Union Ombudsman Nikiforos Diamandouros has called on the European Medicines Agency to increase…

AstraZenecaCandesartan CilexetilCardio-vascularEuropePharmaceuticalRegulationResearchTakeda Pharmaceuticals

Takeda and Pronova highlight TAK-085 Japanese Ph III trial results

19-03-2012

Japanese drug major Takeda Pharmaceutical (TYO: 4502) and Norway-based lipid therapies specialist Pronova…

Cardio-vascularPharmaceuticalPronova BioPharmaResearchTakeda Pharmaceuticals

Takeda's Edarbi set to be gold standard for hypertension

06-03-2012

Based on clinical data and the opinions of interviewed thought leaders, Edarbi (azilsartan medoxomil),…

Cardio-vascularDiovanEdarbiGlobalMarkets & MarketingNovartisPharmaceuticalTakeda Pharmaceuticals

Takeda gets US regulatory backing for Edarbyclor

21-12-2011

The US Food and Drug Administration yesterday approved Edarbyclor (azilsartan medoxomil and chlorthalidone)…

Cardio-vascularEdarbiEdarbyclorNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

Takeda’s Edarbi Oked in EU

12-12-2011

In another piece of positive news for Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502),…

Cardio-vascularEdarbiEuropePharmaceuticalRegulationTakeda Pharmaceuticals

UK’s NICE final guidance backs Takeda’s Mepact and AstraZeneca’s Brilique

26-10-2011

The UK’s National Institute for Health and Clinical Excellence (NICE) issued two final guidances…

AstraZenecaBrilintaBriliqueCardio-vascularEuropeMepactOncologyPharmaceuticalPricingRegulationTakeda Pharmaceuticals

Takeda and Pronova file for triglyceride lowererTAK-085 approval in Japan

29-09-2011

Norway-based lipid therapies specialist Pronova BioPharma says that its partner, Takeda Pharmaceutical…

Asia-PacificCardio-vascularPharmaceuticalRegulationTakeda Pharmaceuticals

Back to top